Literature DB >> 21348768

Pan-resistant Acinetobacter baumannii mediastinitis treated successfully with tigecycline: a case report.

Ayşe Yasemin Tezer Tekçe1, Ayşe Erbay, Hatice Çabadak, Serap Yağcı, Nihal Karabiber, Süha Şen.   

Abstract

BACKGROUND: Mediastinitis due to Acinetobacter baumannii is rare.
METHODS: We report a case of mediastinitis caused by pan-resistant A. baumannii in a patient with multiple comorbidities who underwent cardiopulmonary bypass and we also present a literature review.
RESULTS: Successful treatment consisted of surgical debridement plus drainage, and tigecycline administration for three weeks.
CONCLUSION: Surgical source control along with effective antibiotics is essential in the treatment of mediastinitis. Tigecycline has the potential to be an option for pan-resistant A. baumannii mediastinitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21348768     DOI: 10.1089/sur.2009.063

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  5 in total

1.  High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

Authors:  Justin R Lenhard; Nicholas M Smith; Zackery P Bulman; Xun Tao; Visanu Thamlikitkul; Beom S Shin; Roger L Nation; Jian Li; Jürgen B Bulitta; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 2.  [Rational antibiotic treatment of mediastinitis].

Authors:  A Ambrosch
Journal:  Chirurg       Date:  2016-06       Impact factor: 0.955

3.  Adjunctive Hyperbaric Oxygen Therapy or Alone Antibiotherapy? Methicillin Resistant Staphylococcus aureus Mediastinitis in a Rat Model.

Authors:  Tolga Kurt; Ahmet Vural; Ahmet Temiz; Ersan Ozbudak; Ali Umit Yener; Suzan Sacar; Mustafa Sacar
Journal:  Braz J Cardiovasc Surg       Date:  2015 Sep-Oct

4.  Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection.

Authors:  Tao Pan; Xiaoyun Liu; Shougui Xiang; Wenli Ji
Journal:  Exp Ther Med       Date:  2016-02-08       Impact factor: 2.447

5.  Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials.

Authors:  Hal Tucker; Michele Wible; Ashesh Gandhi; Alvaro Quintana
Journal:  Infect Drug Resist       Date:  2017-11-03       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.